Global Biopharma Company Continues to Invest in Ireland
Alkermes will invest €20m over the next three years to modernise its manufacturing facility based in Athlone.
Alkermes is a global biopharmaceutical company developing innovative medicines for the treatment of the central nervous system (CNS) diseases.
The company employs more than 400 people in Ireland at its manufacturing and drug development facility in Athlone, Co. Westmeath and at its global headquarters operation in Dublin, with more than 1,200 employees worldwide.
Alkermes investment will modernise the existing plant to allow the company to focus primarily on the manufacture of new advanced product lines and position the facility for future growth.
Richard Pops, Chief Executive Officer of Alkermes plc, said: “Ireland has established a solid track record as the ideal location for many of the world’s leading pharmaceutical businesses. We see our Irish base as important to the evolution of our business, both in our European markets and globally”.
As part of the refurbishment Dortek have recently installed more than 93 hygienic doors and 42 observation windows at the site. The range of doors included hygienic hinged and sliding doors, automated doors, fire rated doors, rapid roll doors, transfer hatches and observation windows. Our doors unique seamless design and ledge free windows are critical to meeting strict quality standards.